



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 317 796
A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 88118110.1

(51) Int. Cl.4: G01N 33/532, G01N 33/531,
G01N 33/546, G01N 33/72

(22) Date of filing: 31.10.88

(30) Priority: 09.11.87 US 118566

(71) Applicant: MILES INC.
1127 Myrtle Street
Elkhart Indiana 46514(US)

(43) Date of publication of application:
31.05.89 Bulletin 89/22

(72) Inventor: Lewis, Lynette A.
57417 O'Sage Drive
Goshen, IN 46526(US)
Inventor: Yip, Kin Fai
51194 Creekhaven Drive
Elkhart, IN 46514(US)

(84) Designated Contracting States:
DE FR GB IT

(74) Representative: Dänner, Klaus, Dr. et al
c/o Bayer AG Konzernverwaltung RP
Patentabteilung
D-5090 Leverkusen 1 Bayerwerk(DE)

(54) Preparation of ligand-polymer conjugate having a controlled number of introduced ligands.

(57) A method for chemically coupling a controllable number of ligands, e.g., haptens, to a polymeric material by derivatization of the polymer with an activating agent to introduce a couplable functional group. The derivatization is performed in the presence of a blocking agent which is reactive with the same functionality on the polymer as the activating agent. By reacting the polymer with a mixture of a predetermined ratio of excess amounts of the activating and blocking agents, a controllable number of couplable functional groups are introduced to the polymer for subsequent linkage to the desired ligand. The resulting polymer-ligand conjugates are useful as reagents in immunoassays, particularly immunoturbidimetric assays.

EP 0 317 796 A1

PREPARATION OF LIGAND-POLYMER CONJUGATE HAVING A CONTROLLED NUMBER OF INTRODUCED LIGANDS

BACKGROUND OF THE INVENTION

5 The present invention relates to methods for coupling ligands such as bindable biological substances to polymeric materials. The resulting ligand-polymer conjugates are particularly useful as reagents in binding assays, e.g., immunoassays. More particularly, the invention concerns such coupling methods wherein steps are taken to control in a reproducible manner the number or density of ligands that become linked to the polymeric material.

10 There is a continuing need for improved methods of chemically coupling ligands to polymeric supports, particularly in the preparation of immunoassay reagents. Analytical performance is often dependent upon how well characterized and reproducible such reagents can be prepared. This is particularly true for the agglutinator reagent in an immunoturbidimetric assay.

15 The typical protocol for performing an immunoturbidimetric assay involves setting up a competitive binding reaction between the analyte of interest in the test sample and the agglutinator reagent for binding to antibody against the analyte. The agglutinator reagent comprises a polymer support bearing multiple ligands capable of binding with a particulate reagent bearing anti-analyte antibody. Binding between multiple agglutinator reagent molecules and multiple anti-analyte particles produces an agglutination that is detectable by turbidimetry. Since analyte in the sample competes with this agglutination reaction, as analyte 20 concentration increases, the turbidity of the reaction mixture decreases.

25 Assay performance of the immunoturbidimetric system is dependent upon the consistency of the agglutinator reagent. If the number of ligand moieties coupled to individual polymers varies widely in the reagent population, the size and rate of formation of light scattering centers produced upon agglutination will similarly vary widely. Such variance can introduce a significant error factor in the precision of the assay. Likewise assay sensitivity is affected by variability in the agglutinator reagent. If the average number of ligands per polymer is low, the maximum agglutination in the absence of analyte is of limited detectability. On the other hand, if the ligand density is too high, it becomes difficult for low levels of analyte to effectively compete for binding to the antibody reagent.

30 The prior art attempts to control the number or density of ligands coupled to polymer supports have depended essentially on the ability to control all reaction conditions affecting the coupling reaction such as reactant concentrations and purity, temperature, pH, and time of reaction. The ability to control so many different aspects of the coupling process is not practical considering the types of polymeric materials that are conventionally used. Natural biopolymers such as bovine serum albumin as well as synthetic materials have been used for the preparation of multivalent ligand-polymer conjugates. However, such polymeric 35 materials generally have limited available coupling sites as well as reactivity that is sensitive to slight changes in coupling conditions.

SUMMARY OF THE INVENTION

40

In accordance with the present invention there is provided a method for chemically coupling a controllable number of ligands to a polymeric material. A central step in the method is the derivatization of a repeating functional group on the polymeric material to introduce a controllable proportion of a second functional group which ultimately serves as the point of coupling of the desired ligand moiety. Such controlled introduction of the second functional group is obtained by reacting the polymeric material with a mixture of a predetermined ratio of excess amounts of (1) an activating agent which is reactive with the repeating functional group on the polymer to form a covalent bond and which comprises the second functional group, and (2) a blocking agent which also is reactive with the repeating functional group on the polymer but which does not comprise the second functional group or any equivalent reactive group.

The extent to which the repeating functional groups on the polymeric material are modified to the second, ligand-couplable, group is a reproducible function of the predetermined ratio of the activating and blocking agents in the reaction mixture. The activating and blocking agents compete for reaction with the polymer functional groups. Where the activating agent is successful in coupling to a particular functional

group on the polymer, the ligand-couplable second functional group becomes extended therefrom and available for coupling to the ligand. On the other hand, where the blocking agent is successful in coupling, the polymer functional group is modified to be unreactive with the activating agent without introducing the ligand-couplable second functional group. The use of excess amounts of the activating and blocking agents 5 dictates that the ratio of successful couplings with the activating and blocking agents, respectively, is substantially independent of any other reaction condition and therefore is highly reproducible within narrow limits.

A number of advantages result from the ability of the present method to afford control of the number, and therefore the density, of ligands introduced onto the polymeric material. A principal advantage is simply 10 the reproducibility with which the ligand-polymer conjugate can be prepared, particularly in commercial manufacture. When used as an immunoassay reagent, the ligand density on the conjugate can be optimized for assay performance. As a result, the assay exhibits improved sensitivity and precision due to the ability to attach a controllable high density of ligand on the polymer. This leads to enhanced signal production without substantially affecting the ability of analyte to effectively compete with the ligand-polymer conjugate for binding to antibody.

BRIEF DESCRIPTION OF THE DRAWINGS

20

Fig. 1 is a flow diagram of the embodiment of the present method that is described in the Examples below. Poly(aspartic acid) (I) is prepared and reacted with a diamine activating agent and a monoamine blocking agent to form an amino-functionalized polymer (II) in which m monomeric units are amino-functionalized and the remaining n monomeric units are blocked. Further activation of the amino groups and 25 condensation with a desired ligand (Glc-peptide) yields the ligand-polymer conjugate (III) of controlled ligand density m .

Figs. 2 and 3 are graphical presentations of data showing the relationship between ligand density on the polymer and performance in an agglutination-based immunoassay system.

30

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The starting polymeric material may be of any desired chemical composition and any desired form 35 provided that it comprise a derivatizable repeating functional group. Representative functional groups for this purpose include, without limitation, amino, carboxyl, hydroxyl, epoxy, halide, sulfhydryl, hydrazido, azido and diazonium groups. The polymer can be a homopolymer or a copolymer, and in the latter case will preferably have a high proportion of monomeric units bearing the derivatizable functional group. Generally, the polymeric material will be water soluble since the primary use of the ligand-polymer conjugate is as a 40 reagent in immunoassays performed on aqueous test samples. The polymeric material may, however, be insoluble and of any desirable shape and of essentially any desired molecular weight. For example, the polymer may be a solid surface such as the wall of a reaction vessel, test tube, or microtiter well, or a bead or particle.

The present invention is particularly applicable to the coupling of ligands to water soluble or suspensible polymer materials. Accordingly, the polymer will generally have a molecular weight between about 45 5,000 and about 500,000 daltons, more usually between about 10,000 and about 50,000 daltons. Polymers particularly suited for use in the present method include, without limitation, the water soluble forms of poly-Gantrez, GAF Chemical Co., Wayne, NJ U.S.A.), poly(acrylic acid), poly(acrylic-acrylamide), and carboxymethylcellulose.

The linking reaction between the polymer and the activating and blocking agents can be selected 55 essentially on the basis of convenience. Representative examples of useful linking reactions are condensation of amino and carboxyl groups, alkylation of amino or sulfhydryl groups with alkyl halides, condensation of hydrazido and carboxyl groups, condensation of hydroxyl and carboxyl groups, coupling of amino and diazonium groups, and coupling of epoxy and amino or sulfhydryl groups. It will generally be preferred, but is not required, that the respective group on the activating and blocking agents which reacts and couples covalently to the polymer be the same chemical group. Where these reactive groups are different, their relative reactivities with the derivatizable repeating group on the polymer will be constant and will play a

role, along with the ratio of reactants, in the density of functionalization of the polymer that takes place in the activation/blocking reaction.

The ligand-couplable functional group introduced to the polymer by the activating agent will be selected to provide a relatively selective site for coupling of the ligand. Such functional group will be, for example, an amino, carboxyl, hydroxyl, epoxy, halide, sulphydryl, hydrazido, azido, or diazonium group. Accordingly, the blocking agent will be selected not to comprise a functional group that has any substantial reactivity or equivalence to such ligand-couplable group. It will be understood that a wide variety of activating/blocking agent pairs are useful in the present invention. Without suggesting any limitation of the principle of the present invention, representative examples of such pairs are provided in the indicated list herein.

10

LIST OF REPRESENTATIVE ACTIVATING/BLOCKING AGENT PAIRS

15

20

25

30

35

40

45

50

55


| | <u>Polymer Functionality</u> | <u>Activating Agent</u> | <u>Blocking Agent</u> |
|----|------------------------------|---|--|
| 5 | Carboxyl | $\text{NH}_2\text{-R-NH}_2$ | $\text{NH}_2\text{-R}'$ |
| 10 | Amino | HOOC-R-COOH | $\text{HOOC-R}'$ |
| 15 | Sulphydryl | $\text{ICH}_2\overset{\text{O}}{\parallel}\text{C-R-C(=O)\text{CH}_2I}$ | $\text{ICH}_2\overset{\text{O}}{\parallel}\text{C-R}'$ |
| 20 | Sulphydryl | | |
| 25 | Sulphydryl | | $\text{ICH}_2\overset{\text{O}}{\parallel}\text{C-R}'$ |
| 30 | Epoxy | $\text{NH}_2\text{-R-NH}_2$ or HS-R-SH | $\text{NH}_2\text{-R}'$ or $\text{HS-R}'$ |
| 35 | Hydroxyl | HOOC-R-COOH | $\text{HOOC-R}'$ |
| 40 | Hydroxyl | Cl-R-Cl | $\text{Cl-R}'$ |
| 45 | Chloromethyl | $\text{H}_2\text{N-R-NH}_2$ | $\text{NH}_2\text{-R}'$ |
| 50 | Hydrazido | HOOC-R-COOH | $\text{HOOC-R}'$ |
| 55 | Diazonium | $\text{H}_2\text{NR-NH}_2$ | $\text{NH}_2\text{-R}'$ |

50 In the list of representative pairs of activating and blocking agents, R will preferably be alkylene, e.g., lower (C₁-C₆) alkylene, including branched and linear forms as well as substituted and unsubstituted forms, or substituted or unsubstituted arylene, and R' similarly will preferably be alkyl, e.g., lower alkyl, or aryl.

55 The predetermined ratio of the activating and blocking agents is established with excess amounts of each. By this is intended that the respective amounts of the activating and blocking agent present in the reaction mixture is in excess of that which would result under the conditions of reaction in the covalent linking of all of such agent. It will be preferred to operate in substantial excess of such amount, usually greater than 2-fold excess, and more preferably greater than 10-fold excess, up to as much as 100-fold excess or greater.

A particularly preferred polymer/activating agent/blocking agent system involves poly(aspartic acid) as the polymer base. In the closed ring form as polysuccinimide, this polymer is a homopolymer of repeating monomeric units having a derivatizable carboxyl functionality. The activating and blocking agents are an alkylidiamine and an alkylmonoamine, respectively, wherein alkyl is defined as above.

5 Preferred alkylidiamine activating agents are oxaalkane diamines having from about 2 to about 20 alkylene groups, for example, of the formula:



wherein r and s , respectively, are integers from 2 through 20 and can be the same or different integer. By oxaalkane will be understood a linear chain of two or more alkylene groups linked together by oxygen as an ether linkage. The alkylene groups can be substituted, but preferably are unsubstituted, and can comprise up to as many as 20 alkylene units such as ethylene, propylene, hexylene, and so forth. The repeating alkylene units can be all the same, some the same, or all different along the chain in terms of length and any substituents.

Preferred alkylmonoamine blocking agents are aminoalkanols having from about 2 to about 10 alkylene groups, and include aminopropanol, aminohexanol, and the like. The hydroxyl functionality introduced by coupling of such a blocking agent to the polymer is unreactive in the coupling reactions 20 typically used to link to amino groups, as introduced by the preferred activating agents, and imparts hydrophilic character to assist in maintaining water solubility of the polymer.

The coupling of the desired ligand to the functional group introduced by derivatization of the polymer with the activating agent can be accomplished in any desired manner. It can be desirable, but is not required, that the activating agent be selected to have a functional group that is reactable directly with a 25 desired functionality on the ligand. Alternatively, the coupling can involve conventional homo- or hetero bifunctional linking agents and/or preliminary derivatization of the ligand to introduce a couplable functionality or linking arm. Following are representative ligand-coupling schemes.

1. Coupling of a carboxylic functionalized ligand with an amino functionalized polymer using a condensation reagent such as 1-ethyl-3-(3-dimethyl-amino propyl)-carbodiimide HCl [Previero et al. FEBS letter 33:135 (1973)].

2. Coupling of an active carboxylic ester (active ester of carboxylic acid and N-hydroxysuccinimide) of the functionalized ligand with an amino functionalized polymer. [Anderson, G.W. et al. J. Am. Chem. Soc. 86:1839 (1964)].

3. Coupling of a sulfhydryl functionalized ligand with an active halide (iodoacetyl) functionalized 35 polymer. [Sutoh, K. et al. J. Mol. Biol. 178:323 (1984)].

4. Coupling of a sulfhydryl functionalized ligand with a maleimido functionalized polymer. [Kitagawa, T. et al. J. Biochem 79:233 (1976)].

5. Coupling of an acyl chloride functionalized ligand with a hydroxyl functionalized polymer.

6. Coupling of an aldehyde functionalized ligand with a hydrazido functionalized polymer. [Heitzmann 40 et al Proc. Natl. Acad. Sci. U.S.A. 71:35-37 (1974)].

The ligand to be coupled to the derivatized polymeric material will be understood to be essentially any organic molecule of interest which has a specific binding partner, and will usually have a molecular weight between about 50 and as high as 200,000 daltons, but commonly will be smaller than 100,000 daltons.

45 Since the present invention is particularly designed for preparing an analytical reagent, the ligand will normally be a substance of analytical interest or related by binding interactions to an analyte of interest, e.g., will be a binding partner to the analyte or a binding analog to the analyte, that is, will be bindable by the same binding partner as the analyte. The binding partner for the ligand can be a binding protein, nucleic acid, or the like, and usually will be selected from one of the members of the following types of binding 50 pairs:
 haptens/antibodies; antigens/antibodies; hormones, vitamins, metabolites/receptors; biotin/avidin; carbohydrates/lectins; complementary polynucleotides; and nucleic acid/protein interactions.

The present invention is particularly useful for the coupling of small organic bindable substances having molecular weights between about 100 and about 2,000 daltons, such as haptens and biotin. Haptens can be 55 represented, without limitation, by drugs, metabolites, hormones, vitamins, and the like organic compounds. Haptenic hormones include thyroxine and triiodothyronine. Vitamins include vitamins A, B, e.g., B₁₂, C, D, E and K, folic acid and thiamine. Drugs include antibiotics such as aminoglycosides, netilmicin, penicillin, tetracycline, terramycin, chloromycetin, and actinomycetin; nucleosides and nucleotides such as adenosine

diphosphate (ADP) adenosine triphosphate (ATP), flavin mononucleotide (FMN), nicotinamide adenine dinucleotide (NAD) and its phosphate derivative (NADP), thymidine, guanosine and adenosine; prostaglandins; steroids such as the estrogens, e.g., estriol and estradiol, sterogens, androgens, digoxin, digitoxin, and adrenocortical steroids; and others such as phenobarbital, phenytoin, primidone, ethosuximide, carbamazepine, valproate, theophylline, caffeine, propranolol, procainamide, quinidine, amitriptyline, cortisol, desipramine, disopyramide, doxepin, doxorubicin, nortriptyline, methotrexate, imipramine, lidocaine, procainamide, N-acetylprocainamide, amphetamines, catecholamines, and antihistamines. The haptenic ligand can also be a synthetic or digested fragment of an antigen which comprises an epitope of diagnostic significance, e.g., a peptide residue which is modified or unmodified, for instance, the glycated peptides characteristic of glycated proteins such as hemoglobin A1c.

The product of the present method will have its principal use as a reagent in a binding assay involving the coupled ligand, particularly immunoassays. For example, where the polymer base is a solid macrosupport such as a bead or reaction vessel surface, the ligand can participate in competitive and noncompetitive immunoassays for determining a binding partner for the ligand, e.g., antibody, or a binding analog of the ligand. The present reagent can be employed essentially in any binding assay wherein assay performance is affected by the ability to control the density of ligand on a polymer support material.

A particularly important use of the present invention is to provide a reproducible water soluble or water suspensible agglutinator reagent for use in agglutination-based immunoassay. Such assays are based on measurement of turbidity formed by agglutination between (i) a multivalent antibody reagent comprising an anti-analyte antibody, or a fragment thereof, bound to a water suspensible particle, and (ii) an agglutinator reagent being multiple ligands and prepared according to the present invention wherein the coupled ligand comprises an epitopic binding site for the anti-analyte antibody or fragment, e.g., the ligand is the analyte or an analog thereof capable of being bound by the anti-analyte antibody or fragment. Quantitation is achieved by turbidimetric measurement and comparison to standard results. The use of an agglutinator reagent prepared according to the present invention provides improved precision and sensitivity and decreased reaction times.

The present invention will now be illustrated, but is not intended to be limited, by the following examples.

30

EXAMPLES

Referring to Fig. 1 of the drawing, aspartic acid was polymerized to polysuccinimide (I). The polymer was then reacted with a mixture of alkyl-monoamine and alkyl-diamine to form an amino functionalized poly(aspartic) acid (II). The amino group was further functionalized with 4-(maleimidomethyl)-1-cyclohexanecarboxylic acid-N-hydroxy-succinimide ester (SMCC) to generate a maleimido functionalized poly(aspartic) acid. The sulphydryl group of a glycated peptide (Glc-peptide) was then allowed to react with the maleimido functionalized poly(aspartic) acid to give the multi-Glc-peptide-poly(aspartic) acid (III). The material so prepared was found to cause anti-Glc-peptide antibody coated latex to agglutinate and therefore to be useful in an immunoassay.

Aspartic acid, aminoethanol, SMCC, 4,9-dioxa-1,12-dodecanediamine and dimethylformide (DMF) were obtained from Aldrich Chemical Co., Inc., Milwaukee, WI, USA.

45

A. Preparation of poly(aspartic acid) (I).

This polymer was prepared according to the procedure of Alpert, J. Chromatography 266:23(1983).

50

B. Preparation of amino-functionalized polymer (II).

Aminoethanol and 4,9-dioxa-1,12-dodecanediamine were dissolved in DMF under argon. The solution was treated with a solution of poly(aspartic acid) and DMF. The reaction was stirred at room temperature for 1 hour and then 70 °C for 2 hours. The mixture was then cooled and most of the liquid was removed by evaporation under reduced pressure. The oily residue was washed repeatedly with ether and then warm tetrahydrofuran. The product was solidified and recovered by filtration. The crude product was dissolved in water and the pH was adjusted to neutral. The solution was then purified with a BioRad P6-DG desalting gel

column (BioRad Laboratories, Richmond, CA, USA). Fractions containing the compound (II) were pooled and lyophilized.

The number of amino groups on the polymers was determined by Habeeb's TNBS assay [Anal. Biochem. 14:328-336(1966)]. Results are shown in Table 1.

5

Table 1

| | | <u>Preparations</u> | | |
|----|------------------------------------|---------------------|----------|----------|
| | | <u>A</u> | <u>B</u> | <u>C</u> |
| 10 | Amount of reactant | | | |
| | Polymer (mmoles) | 10 | 10 | 10 |
| 15 | Aminoethanol (mmoles) | 90 | 80 | 50 |
| | 3,4,3-Diamine (mmoles) | 10 | 20 | 50 |
| 20 | Amino groups per mg polymer | | | |
| | Calculated | 13 | 26 | 65 |
| | Actual | 11.7 | 22 | 36.7 |


25

The data demonstrate that the amount of amino groups on the polymer can be controlled by varying the ratio of the alkyl monoamine blocking agent and the alkyl diamine activating agent.

30 C. Preparation of multi-Glc-peptide-poly(aspartic acid(III)).

35 Amino functionalized poly(aspartic acid) and SMCC were dissolved in DMF. The reaction was allowed to stir at room temperature for 2 hours. Ice water was added to the mixture and the activated polymer was separated from the mixture with a BioRad 6P-DG gel column. The activated polymer was then allowed to react at room temperature for 3 minutes with the glycated peptide

40



45

prepared according to the methods described in European Patent Publication 185,870. After the reaction, the product (III) was again purified with a 6P-DG gel column and lyophilized.

The number of maleimido groups on the activated polymers was determined by the PDS assay [Grassetti and Murray, Arch. Biochem. Biophys. 119:44-49(1967)]. The amount of Glc-peptide on the polymers was determined by UV/Vis absorption measurement using 275 nm as the molar extinction coefficient for tyrosine. Results are shown in Table 2.

50

The data show that the number of ligands (Glc-peptide) coupled to the polymer can be controlled by the amount of amino groups on the polymer and the concentration of the other reactants.

55

Table 2

| Amount of reactant | Preparation | | | | |
|--|-------------|-----------|-----------|-----------|-----------|
| | <u>A'</u> | <u>B'</u> | <u>C'</u> | <u>D'</u> | <u>E'</u> |
| Amino-polymer (mg) | 20 | 20 | 20 | 20 | 10.7 |
| Amino groups per mg polymer | 11.7 | 11.7 | 11.7 | 11.7 | 22 |
| SMCC (mg) | 15 | 25 | 25 | 28.5 | 30 |
| Glc-peptide (mg) | 0.1 | 5.2 | 10.4 | 20 | 20 |
| Maleimide groups per polymer (μ mole/mg) | 0.15 | 0.15 | 0.15 | 0.29 | 0.46 |
| Glc-peptide per polymer (μ mole/mg) | 0.02 | 0.093 | 0.19 | 0.26 | 0.46 |
| Glc-peptide/polymer (mole ratio) | 0.4 | 1.9 | 3.8 | 5.2 | 9.4 |

55 D. Latex agglutination reaction

Solutions containing 1.25, 2.5, 5, 10, 20, and 40 μ g/mL of compound (III) from each of Preparations A' to E' in phosphate buffer (20 mM, pH = 6.0, 0.1% BSA, 0.1% NaN_3) were prepared. The solutions were used

as agglutinators. A 25 μ L aliquot of the agglutinator solution was added to a mixture of 0.5 mL of latex coated with antibody to hemoglobin Alc (see European Patent Publication 185,870) and 10 μ L of a mixture of 3M NH₄SCN and 2 mg/ml K₃Fe(CN)₆. The absorption (A) of each reaction at 540 nm was measured after 20 minutes at room temperature. The absorption of antibody-coated latex (Al) without the agglutinator was 5 also measured.

$$\text{Agglutination} = (A/Al) \times 100$$

10 The results of agglutination reactions with different agglutinators are shown in Figs. 2 and 3 of the drawing.

Fig. 2 shows the relationship between the measured agglutination and the amount of various agglutinators in the reaction mixture. The amount of Glc-peptide per mg polymer in the agglutinator is indicated on Fig. 2 next to the respective curves.

15 Fig. 3 shows the relationship between the Glc-peptide/polymer ratio and maximum observed agglutination. The data show that reproducible maximum agglutinations are dependent upon the controlled number of ligand residues on the polymer.

E. Comparison to Prior Art

20 A Glc-peptide-BSA conjugate was prepared, optimized and used in the latex agglutination immunoassay.

25 Bovine serum albumin (BSA, Sigma Co., St. Louis, MO U.S.A., 50 mg, 0.72 μ moles, 44 μ moles-NH₂ groups) was mixed with 4.5 mL phosphate buffer (100 mM, pH=7.0 and 1 mM EDTA). The solution was treated with a solution of SMCC (50 mg, 150 μ moles) dissolved in 0.5 ml dimethylformamide (DMF). The mixture was allowed to react at room temperature for 30 minutes. The reaction mixture was applied to a Sephadex G-25 column (2.5 x 28 cm, Pharmacia Fine Chemicals, Piscataway, NJ U.S.A.), equilibrated with 100 mM phosphate buffer, pH=6.0 and 1 mM EDTA. The first peak collected was found to contain the maleimido-activated BSA. The number of maleimido groups on the activated BSA can be determined by the 30 PDS assay. The activated BSA was then allowed to react at 4 °C with the Glc-peptide, supra (5 mg), for 40 hours. The product was again purified by Sephadex G-25 chromatography. The amount of Glc-peptide linked to BSA was determined by the fructoseamine assay [Johnson et al, Clin. Chem. Acta 127:87(1982)]. The Glc-peptide-BSA conjugate was used in place of compound (III) as the agglutinator reagent in the latex 35 agglutination immunoassay described above.

When BSA was used as the polymeric material in the agglutinator reagent, only 5-10 of the amino groups (out of the possible 61 groups) on the BSA were capable of being functionalized. This conjugate was found to give an agglutination response equivalent to the present compound (III) having a density of 0.19-0.21 μ mole Glc-peptide per mg polymer. This inferior performance is apparently due to the inaccessibility 40 of the other NH₂ groups on BSA.

The present invention has been particularly described and exemplified above. Obviously, many other variations and modifications of the invention can be made without departing from the spirit and scope hereof.

45 Claims

1. A method for chemically coupling a controllable number of ligands to a polymeric material, characterized by the steps of:

- (a) obtaining a polymeric material having a repeating functional group,
- 50 (b) derivatizing the repeating functional groups on the polymeric material to introduce a controllable proportion of a second functional group by reacting the polymeric material with a mixture of a predetermined ratio of excess amounts of (1) an activating agent which is reactive with said repeating functional group to form a covalent bond thereto and which comprises said second functional group, and (2) a blocking agent which also is reactive with said repeating functional groups to form a covalent bond thereto 55 but which does not comprise said second functional group or any equivalent reactive group, and
- (c) coupling said ligands to the polymeric material through the controllable introduced second functional groups.

2. The method of claim 1 wherein the ligands are substances which have a specific protein binding partner, preferably haptens or biotin.
3. The method of any of claims 1 and 2 for preparing a multivalent hapten-polymer conjugate having a controllable number of hapten moieties coupled to the polymer, which method comprises the steps:
 - 5 (a) reacting poly(aspartic acid) with a mixture of a predetermined ratio of excess amounts of a diamine and a monoamine under conditions favorable to the formation of a covalent bond between the repeating carboxyl groups on poly(aspartic acid) and the amine groups on said diamine and monoamine, and
 - 10 (b) coupling the hapten to the derivatized poly(aspartic acid) through the amine functional groups introduced by reaction with the diamine.
4. The method of any of claims 1 to 3 wherein the diamine and monoamine are an alkyldiamine and an alkylmonoamine, respectively; the alkyldiamine preferably being an oxaalkanediamine having from about 2 to about 20 alkylene groups, and the alkylmonoamine preferably being an aminoalkanol having from about 2 to about 10 alkylene groups.
- 15 5. The method of any of claims 1 to 4 wherein the hapten is coupled to the introduced amine groups on poly(aspartic acid) through a bifunctional coupling agent.
6. The method of any of claims 1 to 5 wherein the poly(aspartic acid) is water soluble and has a molecular weight of between about 500 and about 500,000 daltons.
- 20 7. The product prepared by the method of any one of claims 1-6.
8. A method for performing a particle agglutination inhibition immunoassay to determine an analyte in a test sample, wherein the test sample is combined with assay reagents comprising (i) a multivalent antibody reagent comprising an anti-analyte antibody, or a fragment thereof, bound to a water suspensible particle, and (ii) an agglutinator reagent comprising a plurality of epitopic binding sites for the anti-analyte antibody or fragment thereof, and wherein the resulting agglutination of said multivalent antibody reagent is measured as a function of the analyte in the sample, characterized in that the agglutinator reagent is prepared by the method of any of claims 1-6 wherein said ligand is the analyte or an analog thereof capable of being bound by the anti-analyte antibody or fragment thereof.
- 25 30 9. The method of claim 8 wherein the analyte is hemoglobin A1c and said ligand is a glycated peptide corresponding to the glycated peptide sequence in hemoglobin A1c.

35

40

45

50

55




FIG. I




FIG. 2




FIG. 3



EP 88 11 8110

| DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
|--|--|-------------------|---|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int. Cl.4) |
| X | EP-A-0 142 810 (GENETIC SYSTEMS INC.) * Page 5, lines 15-28; page 7, lines 1-8; page 8, line 13 - page 9, line 30; page 10, line 19 - page 12, line 7; page 14, line 2 - page 20, line 27; page 28, line 1 - page 32, line 33; page 33, example 1; page 49, line 1 - page 54, line 24 * | 1-4,7,8 | G 01 N 33/532 G 01 N 33/531 G 01 N 33/546 G 01 N 33/72 |
| X,P | EP-A-0 251 527 (PANAB LABORATORIES INC.) * Page 3, line 31 - page 15, line 56 * | 1-4,7,8 | |
| X | EP-A-0 149 405 (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE) * Page 3, line 37 - page 9, line 16; page 24, line 21 - page 25, line 21 * | 1-4,7,8 | |
| X | EP-A-0 246 446 (BEHRINGWERKE AG) * Page 7, example 3; page 8, claim 1; page 9, claims 7,10 * | 1-4,7,8 | |
| X | EP-A-0 028 132 (DYNASCiences CORP.) * Page 5, line 1 - page 6, line 8; claims 1-5 * | 1-4,7,8 | TECHNICAL FIELDS SEARCHED (Int. Cl.4) |
| X | EP-A-0 178 791 (UNILEVER N.V.) * Page 4, line 22 - page 7, line 25; page 14, line 4 - page 15, line 7 * | 1-4,7,8 | G 01 N |
| X | EP-A-0 077 671 (ORTHO DIAGNOSTIC SYSTEMS) * Page 3, line 30 - page 4, line 10; page 6, line 15 - page 8, line 20; page 9, line 19 - page 11, line 4; page 12, line 4 - page 14, line 19; page 22, line 3 - page 28, line 14 * | 1-4,7,8 | |
| | ---- | -/- | |
| The present search report has been drawn up for all claims | | | |
| Place of search | Date of completion of the search | Examiner | |
| THE HAGUE | 07-03-1989 | VAN BOHEMEN C.G. | |
| CATEGORY OF CITED DOCUMENTS | | | |
| X : particularly relevant if taken alone | T : theory or principle underlying the invention | | |
| Y : particularly relevant if combined with another document of the same category | E : earlier patent document, but published on, or after the filing date | | |
| A : technological background | D : document cited in the application | | |
| O : non-written disclosure | L : document cited for other reasons | | |
| P : intermediate document | & : member of the same patent family, corresponding document | | |



| DOCUMENTS CONSIDERED TO BE RELEVANT | | | CLASSIFICATION OF THE APPLICATION (Int. Cl. 4) | |
|---|---|--|--|--|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int. Cl. 4) | |
| X | GB-A-2 101 630 (SOUTH AFRICAN INVENTIONS DEVELOPMENT CORP.) * Page 2, lines 23-47; page 4, line 28 - page 5, line 2; page 6, lines 16-33; page 16, lines 20-25; page 17, lines 13-30 * --- | 1-4,7,8 | TECHNICAL FIELDS SEARCHED (Int. Cl.4) | |
| X | MACROMOLECULAR CHEMISTRY, RAPID COMMUNICATIONS, vol. 8, 1987, pages 431-435, US; M. YOKOYAMA et al.: "Preparation of adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. A new type of polymeric anticancer agent" * Page 431, lines 21-29; page 434, lines 16-47 * | 3-6 | TECHNICAL FIELDS SEARCHED (Int. Cl.4) | |
| Y | EP-A-0 094 777 (FUJIREBIO K.K.) * Page 2, line 11 - page 3, line 13; page 20, lines 21-25 * | 1-4,7,8 | TECHNICAL FIELDS SEARCHED (Int. Cl.4) | |
| Y | EP-A-0 001 197 (INSTITUTE NATIONAL DE LA RECHERCHE AGRONOMIQUE) * Page 1, line 22 - page 3, line 23; page 12, example 1; page 13, example 2; page 15, example 3; page 17, example 4; page 24, lines 2-8 * | 1-4,7,8 | TECHNICAL FIELDS SEARCHED (Int. Cl.4) | |
| The present search report has been drawn up for all claims | | | TECHNICAL FIELDS SEARCHED (Int. Cl.4) | |
| Place of search | Date of completion of the search | Examiner | TECHNICAL FIELDS SEARCHED (Int. Cl.4) | |
| THE HAGUE | 07-03-1989 | VAN BOHEMEN C.G. | TECHNICAL FIELDS SEARCHED (Int. Cl.4) | |
| CATEGORY OF CITED DOCUMENTS | | T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document | | |
| X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document | | T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document | | |